3Drtieke TB,Barany P,Cazzola M,et al.Management of iron deficiency in renal anemia:guidelines for the optimal therapeutic approach in erythropoietin-treated patients[J].Clin Nephrol,1997,48:1- 8. 被引量：1
4Kalantar-Zadeh K,H(o)ffken B,Wünsch H,et al.Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era[J].Am J Kidney Dis,1995,26:292. 被引量：1
5Kumar R,Kalra SP,Kumar H,et al.Pancytopenia-a six year study[J].J Assoc Physicians India,2001;49:1079-81. 被引量：1
6Zeldis J,Farraye FA,Steinberg HN.In vitro hepatitis B virus suppressionof erythropoiesis is dependent on the multiplicity of infection and is re-versible with anti HBs antibodies[J].Hepatology,1988;8(4):755-9. 被引量：1
7Wang H,Wang X,Xu X,et al.Mean corpuscular volume predicts progno-sis in MDS patients with abnormal karyotypes[J].Ann Hematol,2010;89(7):671-9. 被引量：1
8Holtan SG,Santana-Davila R,Dewald GW,et al.Myelodysplastic syn-dromes associated with interstitial deletion of chromosome 5q:clinicopath-ologic correlations and new insights from the prelenalidomide era[J].AmJ Hematol,2008;83(9):708-13. 被引量：1
9Wimazal F,SperrW R,Kundi M,et al.Prognostic value of lactate dehy-drogenase activity in myelodysplastic syndromes[J].Leuk Res,2001;25(4):287-94. 被引量：1
10Germing U,Hildebrandt B,Pfeilstocker M,et al.Refinement of the inter-national prognostic scoring system(IPSS)by including LDH as an ad-ditional prognostic variable to improve risk assessment in patients withprimary myelodysplastic syndromes(MDS)[J].Leukemia,2005;19(12):2223-31. 被引量：1
